Morpholine → HCID 58255775, compound

Participants

Reaction Conditions

Reaction Steps

N-{2-Chloro-5-[4-({[6-(chloromethyl)-2-pyridinyl]carbonyl}amino)-1-(phenylsulfonyl)-1H-indazol-6-yl]-3-pyridinyl}-6-(chloromethyl)-N-(methylsulfonyl)-2-pyridinecarboxamide (60 mg, 0.061 mmol) and morpholine (0.5 ml, 5.74 mmol) were placed in a vial and heated in a microwave at 90° C. for 15 min. The mixture was concentrated by blow down under a stream of nitrogen. The crude residue was suspended in IPA (2 ml) and 2M NaOH (1 ml) added. The mixture was stirred at room temperature for 2 h. The solvent was removed by blow down and the residue purified by MDAP (Method E) (3×800 μl injections in DMSO, the insoluble salt was filtered off through a filter tube). Product-containing fractions were combined and the solvent removed in vacuo. The residue was dissolved in DCM:MeOH and added to the top of a 1 g silica cartridge that was subsequently eluted with 0-5% MeOH/DCM over 5 column volumes. No separation was observed, hence all fractions were combined and the solvent removed under a stream of nitrogen. The residue was dissolved in DMF/Acetone/Water (0.2 ml:0.2 ml:20 μl) and purified by MDAP (Method E). Product-containing fractions were combined and the solvent removed in vacuo. The resulting oil was triturated with ether to give the title compound as a cream solid (8 mg).

Provenance & Evidence